Anodyne

Pregabalin
Pregabalin
Molecular structure via molpic based on CDK
[]
Enable javascript to view conformer structure via 3Dmol.js
Physical properties
[]
159.23 g/mol [1]
AppearanceWhite to off-white crystalline solid [1]
Melting point186-188 °C [1]
SolubilityFreely soluble [1]
-1.6 [1]
Structural Identifiers
[]
C8H17NO2 [1]
(3S)-3-(aminomethyl)-5-methylhexanoic acid [1]
CC(C)C[C@@H](CC(=O)O)CN [1]
InChI=1S/C8H17NO2/c1-6(2)3-7(5-9)4-8(10)11/h6-7H,3-5,9H2,1-2H3,(H,10,11)/t7-/m0/s1 [1]
InChIKeyAYXYPKUFHZROOJ-ZETCQYMHSA-N [1]
Dosing
[]
Elimination half-life4.5 – 7 hours[4] (mean 6.3 hours)[5]
Duration of action8 – 12 hours [6]

Pregabalin

Pregabalin (also known as (S)-3-(Aminomethyl)-5-methylhexanoic acid, 3-isobutyl GABA, (S)-Pregabalin, Pregabalina, Pregabaline, Vronogabic, Pregabalin mylan, Pregabalin sandoz, Pregabalin zentiva or Pregabalin sandoz gmbh) is a substance of the gabapentinoid class.

Chemistry

Salts []

Pregabalin is typically found in the form of its hydrochloride and sodium salts.

 []

Pregabalin is a absolute mixture

Anodyne Usernotes
[]
0xea / Pregabalin via Baseline ; doesn't prevent

Experience reports []

Legal status []

  • Australia: Pregabalin is a S4 substance.[3]
  • Brazil: Pregabalin is a C1 substance.
  • Canada: Pregabalin is a prescription only substance.
  • New Zealand: Pregabalin is a prescription only substance.
  • United Kingdom: Pregabalin is a prescription only substance.
  • United States: Pregabalin is a Schedule V substance.
  • European Union: Pregabalin is a prescription only substance.

References []

  1. National Center for Biotechnology Information. PubChem Compound Summary for CID 5486971, Pregabalin. Accessed June 26, 2025. https://pubchem.ncbi.nlm.nih.gov/compound/5486971

  2. U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Pregabalin. UNII: 55JG375S6M. Global Substance Registration System. Accessed June 26, 2025. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/55JG375S6M

  3. Prescription medicines: registration of new generic medicines and biosimilar medicines, 2017. June 21, 2022. Accessed June 26, 2025. https://www.tga.gov.au/resources/publication/publications/prescription-medicines-registration-new-generic-medicines-and-biosimilar-medicines-2017

  4. Expert Committee on Drug Dependence Forty-first Meeting. Critical Review Report: Pregabalin. World Health Organization. November 1, 2018. Accessed June 26, 2025. https://www.who.int/medicines/access/controlled-substances/Pregabalin_FINAL.pdf?ua=1

  5. Cross AL, Viswanath O, Sherman AI. StatPearls [Internet]. StatPearls Publishing. July 19, 2022. Accessed June 26, 2025. https://www.ncbi.nlm.nih.gov/books/NBK470341/

  6. BNF Pregabalin. NICE. November 16, 2018. Accessed June 26, 2025. https://bnf.nice.org.uk/drugs/pregabalin/#indications-and-dose